| |
April 3 - 4, 2023 | San Diego, CA Connect with leading communications professionals and have honest, open discussions about how to develop your career in the industry. Early Bird Rate Ends February 10th.
|
|
|
Wednesday, February 15, 2023 | 1pm ET / 10am PT Biosimilars continue to gain global acceptance and momentum. However, the complex and ever-changing regulatory environment is still a challenge. Join industry experts for a discussion on biosimilar regulatory trends and key insights for navigating the biosimilar regulatory landscape. Register now.
|
|
| By Max Bayer,Fraiser Kansteiner Johnson and Johnson's pharmaceutical unit Janssen is undergoing a seismic overhaul, folding its infectious disease team with the vaccines unit and discontinuing numerous programs in the process. As a result, the company expects to lay off employees in several countries. |
|
|
|
By Ben Adams,Zoey Becker,Kevin Dunleavy For the third year in a row, Evaluate Vantage’s most hotly tipped drug approval when it comes to future sales potential is an Alzheimer’s therapy, but there is far more caution in this year’s list than we have seen before. |
By Angus Liu The calls for a new Bayer CEO have been answered. Bill Anderson, most recently Roche’s pharma chief, will become Bayer’s new group CEO starting in June. |
By Nick Paul Taylor The fight for the myasthenia gravis market has become too hot for Sanofi to handle. After reviewing the competitive landscape, the Big Pharma has decided to stop a phase 3 clinical trial of a drug candidate it acquired in its $3.7 billion takeover of Principia Biopharma. |
By Conor Hale,Andrea Park In 2021, light at the end of the COVID tunnel spurred an explosion of medtech deals. But in 2022, that exuberance waned. |
By Teresa Carey This week on "The Top Line," we discuss which companies made the list of the top 10 pharma M&A deals of 2022 and what was at stake last year. We also talk about what last year's biggest deal means for M&A activity this year. |
By Angus Liu An early-stage clinical trial of GSK’s Jemperli in rectal cancer recently attracted interest among media outlets aimed at the general public, including The New York Times. But highlighting two “unprecedented” elements, the FDA is questioning GSK’s proposed regulatory path. |
By Annalee Armstrong,Gabrielle Masson,Max Bayer We had hoped that our Layoff Tracker would stay retired for a while, but 2023 is starting to look a lot like our old friend 2022 when it comes to layoffs in biotech. |
By Annalee Armstrong Johnson & Johnson has yet to publicly detail the R&D overhaul reported last week by Fierce Pharma, and, apparently, at least one company with work that may be deprioritized or reorganized is waiting in the lurch. |
By Angus Liu Contract biopharma manufacturer Catalent has reportedly drawn buyout interest, as dwindling COVID windfall weighs on the business outlook and stock performance. Both Catalent and its reported suitor Danaher have recently doubled down on cell and gene therapies. |
By Andrea Park 3M has developed a new medical product with major staying power. |
By Helen Floersh The new CAR design showed success in mouse models of glioma, bone cancer and lung cancer, making it a must-try in the clinic, the researchers said. |
By Ben Adams Are you a man with a plan or an “internal agonizer”? Those are the questions Endo is asking men in a new campaign aimed at getting people off the internet and into their doctor’s office to talk about a subject that Endo believes has remained taboo for long enough: Peyronie's disease. |
By Annalee Armstrong A week after pausing a leukemia trial due to a patient death, Magenta Therapeutics is halting development of all programs and exploring a potential sale or other measures to wind down operations. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we discuss what we can expect from the obesity market in 2023. We also recap the drugs approved last year. |
|
|---|
|
|
|
Both mutations of proteins and disruption of protein networks can cause diseases. With genes providing the blueprints to make proteins, pairing next-generation sequencing with protein characterization can help researchers identify causal factors for disease and discover and prioritize drug targets. Download this whitepaper to learn more. Down this whitepaper to learn more.
|
|
| Whitepaper Discover the Power of Small with NanoplasmidTM – the next-generation plasmid for manufacturing today’s cell and gene therapies. Sponsored by: Aldevron |
| WhitepaperThis paper explores the cost drivers behind gene therapies and how they are likely to evolve in the coming years. Sponsored by: Blue Matter |
| WhitepaperExploring the biology of G Protein-Coupled Receptors (GPCRs) and outlining a novel approach for developing therapeutics against previously undruggable GPCRs Sponsored by: Orion Biotechnology |
| Whitepaper Learn more about critical success factors for your next launch based on the experience of 100+ pharma product launches. Sponsored by: Herspiegel Consulting |
| WhitepaperRCTs with digital twins require fewer control patients and shorten trial timelines for Alzheimer's disease. Sponsored by: Unlearn AI |
| Whitepaper What makes nucleotides suitable for current good manufacturing practices? Sponsored by: Thermo Fisher Scientific |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| WhitepaperAccelerating bioproduction towards high performance and scale Sponsored by: Capgemini Americas Inc. |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| eBook Catalent’s Carla Vozone discusses the significant trends in the Orally Inhaled & Nasal Drug Delivery (OINDP) segment including large molecules and novel indications. Sponsored By: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
